These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27534768)

  • 1. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building respirable powder architectures: utilizing polysaccharides for precise control of particle morphology for enhanced pulmonary drug delivery.
    Kadota K; Uchiyama H; Kämäräinen T; Tanaka S; Tozuka Y
    Expert Opin Drug Deliv; 2024 Jun; 21(6):945-963. PubMed ID: 38961522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of disposable inhalers in pulmonary drug delivery.
    de Boer AH; Hagedoorn P
    Expert Opin Drug Deliv; 2015 Jan; 12(1):143-57. PubMed ID: 25374325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry powder inhalation, part 2: the present and future.
    de Boer AH; Hagedoorn P; Grasmeijer F
    Expert Opin Drug Deliv; 2022 Sep; 19(9):1045-1059. PubMed ID: 35984322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological and practical challenges of dry powder inhalers and formulations.
    Hoppentocht M; Hagedoorn P; Frijlink HW; de Boer AH
    Adv Drug Deliv Rev; 2014 Aug; 75():18-31. PubMed ID: 24735675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing challenges in respiratory therapies.
    Yeung S; Traini D; Lewis D; Young PM
    Int J Pharm; 2018 Sep; 548(1):659-671. PubMed ID: 30033395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of dry powder inhalers to improve patient outcomes: it's not just about the device.
    Weers JG
    Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 14. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
    Rawal T; Kremer L; Halloum I; Butani S
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.